Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Clinical Phase I dosing of Glenmark Pharmaceuticals’ GNR 830 completed in Netherlands By PBR Staff Writer
Glenmark Pharmaceuticals, a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals, has completed the clinical Phase 1 dosing of its GBR 830, a monoclonal antibody, in the Netherlands.
Contract Research & Services > Clinical Trials > News
Suven starts phase 1 clinical trial of Alzheimer's drug in US By PBR Staff Writer
Biopharmaceutical firm Suven Life Sciences has started phase-1 clinical trial for SUVN-D4010, used for cognition in Alzheimer's disease.
Contract Research & Services > Clinical Trials > News Heat Biologics starts clinical trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC Heat Biologics has enrolled the first patient in a Phase 1b clinical trial investigating the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab (Opdivo) in non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Viking Therapeutics starts VK5211 clinical development program
By PBR Staff Writer
Biopharmaceutical firm Viking Therapeutics has started VK5211 clinical development program for muscle and bone disorders.
Contract Research & Services > Clinical Trials > News
Woodley Equipment to Attend Outsourcing in Clinical Trials Nordics Conference 2015
Woodley Equipment is attending Outsourcing in Clinical Trials Nordics Conference taking place at the Crowne Plaza Copenhagen Towers Hotel, Copenhagen, Denmark from 9 -10th September 2015.
Contract Research & Services > Clinical Trials > Press Releases
MicuRX reports positive Phase II trial results for MRX-I to treat MRSA and VRE
By PBR Staff Writer
MicuRx Pharmaceuticals has reported positive top-line results from the first Phase II clinical trial for its lead drug MRX-I, an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Contract Research & Services > Clinical Trials > News
Symbiomix completes enrollment in second pivotal trial of SYM-1219 for bacterial vaginosis
Symbiomix announced the completion of patient enrollment in a Phase 3 clinical study, the second pivotal trial of SYM-1219, which is a single-dose, oral product candidate for the treatment of bacterial vaginosis (BV).
Contract Research & Services > Clinical Trials > News
Biohaven begins dosing in Phase I trial with lead drug candidate BHV-0223
By PBR Staff Writer
Portage's subsidiary Biohaven Pharmaceutical has started dosing in a Phase I trial to evaluate the safety and pharmacokinetic characteristics of BHV-0223, a glutamate modulating agent, in humans.
Contract Research & Services > Clinical Trials > News
Threshold begins Phase II trial tarloxotinib to treat head and neck or skin cancers
By PBR Staff Writer
Threshold Pharmaceuticals has started a Phase II trial of tarloxotinib bromide or 'tarloxotinib' (TH-4000), to treat patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
Contract Research & Services > Clinical Trials > News
NEJM publishes GSK's Phase IIIb/IV study of ambrisentan and tadalafil to treat PAH patients
GSK today announced publication of the AMBITION study, the first outcomes study to compare the safety and efficacy of investigational first-line combination therapy of Volibris (ambrisentan) and Adcirca (tadalafil) to first-line monotherapy of either treatment alone in treatment-naïve patients with pulmonary arterial hypertension (PAH).
Contract Research & Services > Clinical Trials > News
Oncolytics completes enrollment in randomized phase II NSCLC trial
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211).
Contract Research & Services > Clinical Trials > News
Syndax, Genentech enter clinical trial collaboration in cancer immunotherapy
By PBR Staff Writer
US-based Syndax Pharmaceuticals and Genentech, a member of the Roche Group, have entered into clinical trial collaboration in cancer immunotherapy combining entinostat and atezolizumab.
Contract Research & Services > Clinical Trials > News
Corium begins Phase I trial of Corplex Donepezil transdermal system to treat Alzheimer's disease
Corium International (CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced the commencement of dosing in a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of Corplex Donepezil Transdermal System for the sustained and controlled delivery of a treatment for Alzheimer's disease.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests